| Literature DB >> 17011337 |
Liza B Vazquez-Cobian1, Thomas Flynn, Thomas J A Lehman.
Abstract
Fourteen children with uveitis (9 JIA associated and 5 idiopathic) were treated with adalimumab for an average of 18.1 months. Inflammation decreased in 21/26 eyes (80.8%), 4 eyes remained stable (15.4%), and 1 worsened (3.8%) (P < .001; 2 tailed paired Wilcoxon rank sum test). No significant adverse events occurred.Entities:
Mesh：
Substances：
Year: 2006 PMID： 17011337 DOI： 10.1016/j.jpeds.2006.04.058
Source DB: PubMed Journal: J Pediatr ISSN： 0022-3476 Impact factor: 4.406